Literature DB >> 23857664

Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.

Qian-Hua Li1, Lie Dai, Zhao-Xia Li, Hai-Jun Liu, Chan-Juan Zou, Xia Ou-Yang, Meng Lu, Ting Li, Yan-Hua Li, Yin-Qian Mo, H Ralph Schumacher.   

Abstract

This study aims to investigate the disease-related knowledge of gout patients and doctors in south China and to identify the important targets of education for patients and doctors. A cross-section survey of 154 primary gout patients and 185 doctors who may see gout patients was conducted with a modified questionnaire with ten items of gout-related knowledge. The participants were considered to have gout-related knowledge if he or she correctly answered seven or more items. One hundred and forty-nine valid questionnaires from patients, 33 from rheumatology physicians, and 151 from non-rheumatology doctors were collected for statistical analysis. The mean correctly answered items of three groups were 6.6 ± 2.2, 9.6 ± 0.53, and 8.0 ± 1.4, with rate of being considered to have knowledge about gout 51.7, 100, and 90.1 %, respectively (P < 0.05). The correct answer rate for each particular item was over 80 % in the rheumatology physician group. Patients or non-rheumatology doctors knew the optimal serum uric acid (sUA) level (48.3 vs 55.6 %), the need to take lifelong urate-lowering drugs (29.5 vs 43.6 %), that allopurinol is a urate-lowering drug (55.7 vs 76.0 %), and how to prevent attacks induced by urate-lowering therapy (ULT) (60.4 vs 74.0 %). Logistic regression showed that higher education predicted which patients had gout-related knowledge. Both the gout patients and non-rheumatology doctors in south China had poor knowledge on ULT. Since many gout patients do not see rheumatologists, our data suggest that further education should focus on patients and non-rheumatologists and emphasize the use of urate-lowering drugs, treatment duration, the target sUA level, and prophylaxis against acute attacks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23857664     DOI: 10.1007/s10067-013-2333-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

Authors:  Eliseo Pascual; Francisca Sivera
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

3.  Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment.

Authors:  H Yamanaka; R Togashi; M Hakoda; C Terai; S Kashiwazaki; T Dan; N Kamatani
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

4.  Patients and providers view gout differently: a qualitative study.

Authors:  Leslie R Harrold; Kathleen M Mazor; Sarah Velten; Ira S Ockene; Robert A Yood
Journal:  Chronic Illn       Date:  2010-07-30

5.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

Review 6.  Chronic gout: epidemiology, disease progression, treatment and disease burden.

Authors:  Richard A Brook; Anna Forsythe; James E Smeeding; N Lawrence Edwards
Journal:  Curr Med Res Opin       Date:  2010-11-04       Impact factor: 2.580

7.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

8.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

9.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

Authors:  Fernando Perez-Ruiz; Marcelo Calabozo; Jose I Pijoan; Ana M Herrero-Beites; Ana Ruibal
Journal:  Arthritis Rheum       Date:  2002-08

10.  Quality of life and disability in patients with treatment-failure gout.

Authors:  Michael A Becker; H Ralph Schumacher; Katy L Benjamin; Peter Gorevic; Maria Greenwald; Jeffrey Fessel; Lawrence Edwards; Ariane K Kawata; Lori Frank; Royce Waltrip; Allan Maroli; Bill Huang; John S Sundy
Journal:  J Rheumatol       Date:  2009-03-30       Impact factor: 4.666

View more
  6 in total

1.  Gout: from international guidelines to current practice. Results from a physician questionnaire.

Authors:  Tristan Pascart; René-Marc Flipo
Journal:  Clin Rheumatol       Date:  2013-11       Impact factor: 2.980

2.  Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies.

Authors:  Sharan K Rai; Hyon K Choi; Sally H J Choi; Anne F Townsend; Kam Shojania; Mary A De Vera
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

3.  The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.

Authors:  Rulan Yin; Haixia Cao; Ting Fu; Qiuxiang Zhang; Lijuan Zhang; Liren Li; Zhifeng Gu
Journal:  Rheumatol Int       Date:  2017-05-27       Impact factor: 2.631

4.  [Development and clinical application of the health education knowledge assessment questionnaire for gout].

Authors:  X W Xie; F Li; G H Ling; X Xie; S Q Xu; Y Y Chen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

5.  Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice.

Authors:  Bart Spaetgens; Tobias Pustjens; Lieke E J M Scheepers; Hein J E M Janssens; Sjef van der Linden; Annelies Boonen
Journal:  Clin Rheumatol       Date:  2016-02-22       Impact factor: 2.980

6.  A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.

Authors:  Jane C Richardson; Jennifer Liddle; Christian D Mallen; Edward Roddy; Samantha Hider; Suman Prinjha; Sue Ziebland
Journal:  BMC Musculoskelet Disord       Date:  2016-06-06       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.